Darovasertib and crizotinib deliver a survival signal in first-line metastatic uveal melanoma
Metastatic uveal melanoma has long occupied one of oncology’s most difficult corners. Once the disease spreads, therapeutic options remain thin, and the biology is often driven by GNAQ/11 mutations that activate protein kinase C signaling in the vast majority of tumors. In that setting, the OptimUM-01 phase I/II study offers a clinically relevant readout for a targeted oral combination built to interrupt the pathway at two points: darovasertib, a first-in-class PKC inhibitor, and crizotinib, a MET inhibitor.
The phase II expansion focused on previously untreated patients with metastatic uveal melanoma and used a clear frontline framework: measurable disease by RECIST v1.1, ECOG performance status 0 to 1, and adequate organ function. Forty-four treatment-naïve patients entered this analysis. The regimen tested was darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily. In a disease where treatment choices often amount to short-lived disease stabilization or modest response rates, even a modest but durable signal deserves close attention.
The efficacy profile leaned in the direction clinicians want to see in first-line treatment: responses, disease control, and survival all moved in a favorable direction.
Response depth and disease control with a dual-pathway approach
The objective response rate reached 34.1%, a notable figure in metastatic uveal melanoma, where tumor shrinkage has historically been elusive. Disease control at 8 weeks was 90.2%, suggesting that the combination did more than produce isolated partial responses; it held a large share of tumors in check early in treatment. Duration of response measured 9.0 months, which matters in a malignancy where early regression can be fleeting if the biologic pressure is not sustained.
Those results fit the mechanistic logic of the regimen. PKC activation sits downstream of the initiating GNAQ/11 alterations, and MET signaling may contribute to escape biology or adaptive survival. Blocking both pathways can plausibly blunt proliferation and reduce the tumor’s ability to compensate after single-pathway inhibition. In practical terms, that means the regimen is not simply aiming to slow growth; it is attempting to interrupt a signaling network that the tumor depends on for persistence.
The median progression-free survival was 7.0 months, with a 95% CI of 5.0 to 8.3 months. Median overall survival reached 21.1 months, with a 95% CI of 11.9 to 20.7 months. The apparent confidence interval overlap in the reported OS estimate should be interpreted cautiously as presented, but the survival figure itself is clinically meaningful in a disease with limited frontline options and historically poor outcomes after metastatic spread. A median OS beyond 20 months in this setting suggests the combination may be changing the tempo of the disease rather than merely delaying progression by a few weeks.
Toxicity was common, but discontinuation remained uncommon
The safety profile was active, and the adverse-event burden was hard to miss. Diarrhea occurred in 95.2% of patients, nausea in 84.1%, peripheral edema in 61.4%, and vomiting in 52.3%. Those toxicities are consistent with an oral targeted therapy regimen that affects signaling pathways with broad physiologic roles, especially in the gastrointestinal tract and vasculature.
Two grade 3 or higher events stood out most clearly: pulmonary embolism in 9.1% of patients and iron deficiency anemia in 6.8%. The thromboembolic signal deserves careful clinical attention because it raises management questions beyond routine symptom control. Patients with metastatic melanoma already carry baseline clotting risk, and any increase in embolic events can complicate treatment delivery, imaging interpretation, and overall performance status. Anemia, especially when severe, can erode functional reserve in a population already facing metastatic disease burden.
Treatment discontinuation because of adverse events occurred in three patients, or 6.8%. In a regimen with frequent gastrointestinal toxicity and notable grade 3 events, that discontinuation rate suggests the combination remained usable for most patients, although “manageable” should not be mistaken for mild. The burden of nausea, diarrhea, vomiting, and edema can matter as much as the laboratory-defined grade in day-to-day practice, because sustained oral therapy depends on adherence and the patient’s ability to keep eating, hydrating, and functioning.
Why this regimen matters in a disease with few frontline options
Uveal melanoma is biologically distinct from cutaneous melanoma, and it has not responded to the same therapeutic playbook with comparable success. The high prevalence of GNAQ/11 mutations creates a rational target, but rational targets do not guarantee clinical success. What makes OptimUM-01 important is the alignment between disease biology and observed activity: a targeted combination aimed at the core signaling abnormality produced measurable responses, prolonged disease control in many patients, and a median overall survival that compares favorably with the grim expectations often attached to metastatic uveal melanoma.
The first-line setting adds another layer of relevance. Patients who start treatment before heavy pretreatment exposure often have better tolerance and more preserved organ function, which can make a biologically active regimen look stronger than it might later in the disease course. Even so, the study enrolled previously untreated patients under standard measurable-disease and performance-status criteria, making the population clinically recognizable rather than artificially selected for exceptional fitness.
For oncologists, the central question is whether the combination can hold its place as an early therapeutic option while safety is refined and confirmatory studies mature. The response and survival numbers argue that the regimen has moved beyond a preclinical concept. The toxicity profile argues that implementation will require active monitoring, especially for gastrointestinal intolerance, edema, anemia, and thromboembolic complications.
The remaining clinical test is durability under real-world pressure
OptimUM-01 provides an encouraging phase II snapshot, not a final answer. The study was open-label and focused on a relatively small cohort of 44 patients, so the precision of the efficacy and safety estimates remains limited. Longer follow-up, broader patient experience, and comparative data will be needed to determine how much of the survival signal reflects the regimen itself and how much reflects the favorable biology and baseline fitness of the treated cohort.
Even with those limits, the trial establishes an important clinical fact: darovasertib plus crizotinib produced frontline activity in metastatic uveal melanoma that is difficult to ignore. The combination generated a substantial disease-control rate, a response rate above the modest thresholds typically seen in this disease, and an overall survival estimate that suggests real clinical movement. Whether it becomes a durable standard will depend on how well the regimen balances efficacy against the gastrointestinal and thromboembolic toxicity it clearly carries.
That balance is the next critical question for patients who have few other options and for clinicians trying to turn pathway biology into practical treatment benefit.